<DOC>
	<DOCNO>NCT01907373</DOCNO>
	<brief_summary>Hypertension hyperuricaemia widespread condition . There significant overlap two condition . Serum uric acid ( SUA ) currently recognize risk factor cardiovascular disease . Thus , point therapy , hypertensive patient hyperuricaemia likely require concurrent treatment anti-hypertensive hypouricaemic agent . For reason , important determine whether pharmacokinetic interaction result concomitant administration agents.Olmesartan angiotensin II receptor antagonist effective well tolerate treatment arterial hypertension . Probenecid well-established hypouricaemic agent treatment hyperuricaemia gout.The goal study examine impact coadministration probenecid pharmacokinetic parameter tolerability olmesartan healthy volunteer .</brief_summary>
	<brief_title>Drug Interaction Study Olmesartan Healthy Chinese Volunteers</brief_title>
	<detailed_description>Probenecid well-established hypouricaemic agent treatment hyperuricaemia gout think act urate transporter 1 ( URAT1 ) , novel member organic anion transporter ( OAT ) family , thereby increase uric acid excretion kidney block urate reuptake , , result decrease SUA . Olmesartan angiotensin II receptor antagonist effective well tolerate treatment arterial hypertension . Olmesartan orally administer prodrug form , olmesartan medoxomil , convert pharmacologically-active compound olmesartan upon de-esterification enzyme arylesterase intestinal wall , portal blood , liver . Olmesartan excrete hepatobiliary renal system without metabolism , pharmacokinetic profile affect age gender . In addition , pharmacokinetic pharmacodynamic profile olmesartan favorable , term provide effective 24-hour blood pressure ( BP ) control once-daily dosing , restrict likelihood pharmacokinetic interaction drug . Studies vitro show organic anion transport polypeptide 1B1 ( OATP1B1 ) , OATP1B3 , multidrug resistance-associated protein 2 ( MRP 2 ) , breast cancer resistance protein ( BCRP ) involve hepatobiliary renal transport olmesartan . We know probenecid interferes kidney ' organic anion transporter ( OAT ) . Will probenecid effect pharmacokinetics olmesartan thereby result change antihypertensive effect side effect olmesartan ? Until , many clinical study show olmesartan pharmacokinetic interaction drug ; moreover , research interaction olmesartan probenecid . In study , assess involvement probenecid pharmacokinetics tolerability olmesartan .</detailed_description>
	<mesh_term>Olmesartan</mesh_term>
	<mesh_term>Olmesartan Medoxomil</mesh_term>
	<mesh_term>Probenecid</mesh_term>
	<criteria>write informed consent obtain , age 18 40 year body mass index 19 25 kg/m2 ; negative test result HIV hepatitis Ð’ C nonsmoking status unremarkable clinical history history evidence renal , gastrointestinal , hepatic , hematologic abnormality acute chronic disease , allergy drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>olmesartan</keyword>
	<keyword>probenecid</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>tolerability</keyword>
</DOC>